2018 Lymphoma Study Group and Hematology Highlights: A Post ASH Review

lsg-ash-landing.jpg

February 2-3, 2018  |  Hilton Omaha

Conference Description

This is a regional conference that has been sponsored by the University of Nebraska Medical Center for the last 11 years.The conference is designed to update the target audience on new treatments and management of acute and chronic leukemia, thrombosis/hemostasis, lymphoma, multiple myeloma, myelodysplastic syndromes, and myeloproliferative disorders as presented during the 2017 annual meeting of the American Society of Hematology.  Presentations will be delivered by key leaders while allowing the opportunity for participants to be involved in the interactive question/answer sessions.

Download agenda »


Target Audience

These activities are intended for physicians, nurse practitioners, physician assistants, nurses, residents, and fellows in the specialty areas of oncology, hematology, internal medicine, radiation oncology, and pathology.


Conference Objectives

At the conclusion of these activities, the participant should be able to:

  1. Provide an update on the incorporation of novel therapies into the care of multiple myeloma patients
  2. Discuss recent trials of therapy for hematologic malignancies including lymphoma, acute and chronic leukemia, myelodysplastic syndromes, myeloproliferative neoplasms, and multiple myeloma
  3. Review emerging data regarding new clinical, genetic, and molecular prognostic factors, and how to use them for precision approaches for the treatment of hematologic malignancies
  4. Discuss results of new targeted agents for hematologic malignancies, as well as their mechanism of action and toxicities
  5. Identify recent trials of therapy and new agents for hemostasis and thrombosis
  6. Describe the role of autologous and allogeneic hematopoietic stem cell transplantation for various hematologic malignancies
  7. Discuss emerging technologies such as CAR-T cell therapy
  8. Use the findings from the 2017 ASH meeting to apply evidence-based medicine to assist practitioners in managing hematologic malignancies and disorders of thrombosis and hemostasis

Continuing Education Credit

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Lymphoma Study Group
The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is provided for 1.0 contact hour under ANCC criteria.

Hematology Highlights: A Post ASH Review
The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is provided for 4.0 contact hours under ANCC criteria.